Key takeaways
Qelbree (viloxazine) and Vyvanse (lisdexamfetamine) are both medications used to treat attention-deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older. However, they belong to different medication classes. Qelbree is a selective norepinephrine reuptake inhibitor (NRI), while Vyvanse is a stimulant. Vyvanse is also FDA-approved to treat moderate-to-severe binge eating disorder (BED) in adults, whereas Qelbree is not. Qelbree is taken once daily and is not a controlled substance. In contrast, Vyvanse is a Schedule II controlled substance due to its high potential for misuse and dependence. Qelbree is only available as a brand-name medication, while Vyvanse is available in both brand and generic forms. Common side effects of Qelbree include sleep problems, headache, and nausea, while Vyvanse can cause a low appetite, difficulty sleeping, and dry mouth. Both medications have significant drug interactions, so be sure your prescriber and pharmacist have a complete list of your medications.
